PSADTime ≤6 months Identifies High-Risk BRPC Patients after Prostatectomy
Ravi A Madan, Clinical researcher focused on Prostate Cancer at National Cancer Institute, shared on X:
“Since EMBARK data there is a need to define high risk BCR Prostate Cancer.
Best data I have seen comes from John Hopkins Medicine team.
Risk of mets at 5 years is only 26% for PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos.”
Mark C. Markowski, Genitourinary Oncologist, Associate Professor, Director of GU Oncology in the National Capital Region at Johns Hopkins SKCCC, shared this post on X, adding:
“Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.”
Authors: Daniel L. Suzman, Jennifer Cullen, Bruce J. Trock, Yongmei Chen, Inger L. Rosner, Zhaoyong Feng, Emmanuel S. Antonarakis, Misop Han, Alan W. Partin, Lauren Hurwitz, Huai-Ching Kuo, David G.McLeod, and Mario A. Eisenberger
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023